ES2204295B1 - Nuevos derivados de quinuclidina-amida. - Google Patents
Nuevos derivados de quinuclidina-amida.Info
- Publication number
- ES2204295B1 ES2204295B1 ES200201539A ES200201539A ES2204295B1 ES 2204295 B1 ES2204295 B1 ES 2204295B1 ES 200201539 A ES200201539 A ES 200201539A ES 200201539 A ES200201539 A ES 200201539A ES 2204295 B1 ES2204295 B1 ES 2204295B1
- Authority
- ES
- Spain
- Prior art keywords
- hydroxy
- group
- octane
- azoniabicyclo
- azabicyclo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- OZCJTNLELXWUTQ-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octane-2-carboxamide Chemical class C1CN2C(C(=O)N)CC1CC2 OZCJTNLELXWUTQ-UHFFFAOYSA-N 0.000 title claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 83
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 102000007202 Muscarinic M3 Receptor Human genes 0.000 claims abstract description 8
- 108010008405 Muscarinic M3 Receptor Proteins 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 139
- -1 hydroxy, methyl Chemical group 0.000 claims description 63
- 239000000203 mixture Substances 0.000 claims description 44
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 21
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 20
- 125000001424 substituent group Chemical group 0.000 claims description 17
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 125000005843 halogen group Chemical group 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 13
- 125000004122 cyclic group Chemical group 0.000 claims description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 125000004429 atom Chemical group 0.000 claims description 9
- ZJSWMRJWTWJORH-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-hydroxy-2,2-dithiophen-2-ylacetamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 ZJSWMRJWTWJORH-ZDUSSCGKSA-N 0.000 claims description 9
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 8
- 125000003342 alkenyl group Chemical group 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims description 7
- PSFULERNVNPNAD-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-9-hydroxyfluorene-9-carboxamide Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1(O)C(=O)NC1C(CC2)CCN2C1 PSFULERNVNPNAD-UHFFFAOYSA-N 0.000 claims description 7
- RRBQMQSYNDZVOX-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-9h-xanthene-9-carboxamide Chemical compound C12=CC=CC=C2OC2=CC=CC=C2C1C(=O)NC1C(CC2)CCN2C1 RRBQMQSYNDZVOX-UHFFFAOYSA-N 0.000 claims description 7
- RRBQMQSYNDZVOX-KRWDZBQOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-9h-xanthene-9-carboxamide Chemical compound C12=CC=CC=C2OC2=CC=CC=C2C1C(=O)N[C@@H]1C(CC2)CCN2C1 RRBQMQSYNDZVOX-KRWDZBQOSA-N 0.000 claims description 7
- RRBQMQSYNDZVOX-QGZVFWFLSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-9h-xanthene-9-carboxamide Chemical compound C12=CC=CC=C2OC2=CC=CC=C2C1C(=O)N[C@H]1C(CC2)CCN2C1 RRBQMQSYNDZVOX-QGZVFWFLSA-N 0.000 claims description 7
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical group C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 claims description 7
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 6
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 6
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 6
- 150000001450 anions Chemical class 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- ZJSWMRJWTWJORH-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-2-hydroxy-2,2-dithiophen-2-ylacetamide Chemical compound C1N(CC2)CCC2C1NC(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 ZJSWMRJWTWJORH-UHFFFAOYSA-N 0.000 claims description 6
- MRVIDGHWQMMOKY-LBAQZLPGSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2,3-diphenylpropanamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(C=1C=CC=CC=1)CC1=CC=CC=C1 MRVIDGHWQMMOKY-LBAQZLPGSA-N 0.000 claims description 6
- KAAGSRJOWSBERT-LROBGIAVSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-cyclopentyl-2-hydroxy-2-phenylacetamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(C=1C=CC=CC=1)(O)C1CCCC1 KAAGSRJOWSBERT-LROBGIAVSA-N 0.000 claims description 6
- MFPPFFMHFODFQO-KNVGNIICSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-hydroxy-2-thiophen-2-ylpent-4-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(CC=C)(O)C1=CC=CS1 MFPPFFMHFODFQO-KNVGNIICSA-N 0.000 claims description 6
- JWODCCLBIXEZOF-OGZJWECNSA-N n-[(3s)-1-(cyclohexylmethyl)-1-azoniabicyclo[2.2.2]octan-3-yl]-9h-xanthene-9-carboxamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.C([C@H](C(CC1)CC2)NC(=O)C3C4=CC=CC=C4OC4=CC=CC=C43)[N+]21CC1CCCCC1 JWODCCLBIXEZOF-OGZJWECNSA-N 0.000 claims description 6
- ZJSWMRJWTWJORH-CYBMUJFWSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-2-hydroxy-2,2-dithiophen-2-ylacetamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 ZJSWMRJWTWJORH-CYBMUJFWSA-N 0.000 claims description 6
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims description 6
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 6
- KTLRLWOABDNXBI-UHFFFAOYSA-N 9-hydroxy-n-(1-methyl-1-azoniabicyclo[2.2.2]octan-3-yl)fluorene-9-carboxamide;bromide Chemical compound [Br-].C12=CC=CC=C2C2=CC=CC=C2C1(O)C(=O)NC(C1)C2CC[N+]1(C)CC2 KTLRLWOABDNXBI-UHFFFAOYSA-N 0.000 claims description 5
- 125000003368 amide group Chemical group 0.000 claims description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- MDSAFGBQDVEKGD-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2,2-dithiophen-2-ylacetamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(C=1SC=CC=1)C1=CC=CS1 MDSAFGBQDVEKGD-ZDUSSCGKSA-N 0.000 claims description 5
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000001624 naphthyl group Chemical group 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 5
- 229920002554 vinyl polymer Polymers 0.000 claims description 5
- HMMFYOXCKMHKFL-JXJWEVJGSA-N 2-hydroxy-n-[(3r)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-3-yl]-2,2-dithiophen-2-ylacetamide;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)NC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CCCOC1=CC=CC=C1 HMMFYOXCKMHKFL-JXJWEVJGSA-N 0.000 claims description 4
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 230000008485 antagonism Effects 0.000 claims description 4
- 229910052749 magnesium Inorganic materials 0.000 claims description 4
- 230000000241 respiratory effect Effects 0.000 claims description 4
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 claims description 3
- YZCFWWYSYVLNNC-DVWUEADGSA-N 2-hydroxy-2,2-dithiophen-2-yl-n-[(3r)-1-(3-thiophen-2-ylpropyl)-1-azoniabicyclo[2.2.2]octan-3-yl]acetamide;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)NC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CCCC1=CC=CS1 YZCFWWYSYVLNNC-DVWUEADGSA-N 0.000 claims description 3
- KAMDIYYBDDEUPF-UHFFFAOYSA-N 2-hydroxy-n-(1-methyl-1-azoniabicyclo[2.2.2]octan-3-yl)-2,2-dithiophen-2-ylacetamide;bromide Chemical compound [Br-].C1C[N+](C)(C2)CCC1C2NC(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 KAMDIYYBDDEUPF-UHFFFAOYSA-N 0.000 claims description 3
- QTQTVZHMXYTWLO-OUIHKFQYSA-N 2-hydroxy-n-[(3r)-1-(2-phenoxyethyl)-1-azoniabicyclo[2.2.2]octan-3-yl]-2,2-dithiophen-2-ylacetamide;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)NC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CCOC1=CC=CC=C1 QTQTVZHMXYTWLO-OUIHKFQYSA-N 0.000 claims description 3
- FCKGLDDAFOKBPB-XPTDNKBGSA-N 2-hydroxy-n-[(3r)-1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-3-yl]-2,2-dithiophen-2-ylacetamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.C([C@@H](C(CC1)CC2)NC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CCOCC1=CC=CC=C1 FCKGLDDAFOKBPB-XPTDNKBGSA-N 0.000 claims description 3
- ZOQNBZKVHYFHGD-XPTDNKBGSA-N 2-hydroxy-n-[(3r)-1-(3-phenylpropyl)-1-azoniabicyclo[2.2.2]octan-3-yl]-2,2-dithiophen-2-ylacetamide;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)NC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CCCC1=CC=CC=C1 ZOQNBZKVHYFHGD-XPTDNKBGSA-N 0.000 claims description 3
- UODVIQPJYLVBDW-IZDPNCFFSA-N 2-hydroxy-n-[(3r)-1-methyl-1-azoniabicyclo[2.2.2]octan-3-yl]-2,2-dithiophen-2-ylacetamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.N([C@@H]1C2CC[N+](CC2)(C1)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 UODVIQPJYLVBDW-IZDPNCFFSA-N 0.000 claims description 3
- HMMFYOXCKMHKFL-PIJXPWFJSA-N 2-hydroxy-n-[(3s)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-3-yl]-2,2-dithiophen-2-ylacetamide;bromide Chemical compound [Br-].C([C@H](C(CC1)CC2)NC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CCCOC1=CC=CC=C1 HMMFYOXCKMHKFL-PIJXPWFJSA-N 0.000 claims description 3
- HMMFYOXCKMHKFL-UHFFFAOYSA-N 2-hydroxy-n-[1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-3-yl]-2,2-dithiophen-2-ylacetamide;bromide Chemical compound [Br-].C=1C=CSC=1C(C=1SC=CC=1)(O)C(=O)NC(C(CC1)CC2)C[N+]21CCCOC1=CC=CC=C1 HMMFYOXCKMHKFL-UHFFFAOYSA-N 0.000 claims description 3
- IBDTWHHILKDNOJ-UHFFFAOYSA-N 9-hydroxy-n-[1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-3-yl]fluorene-9-carboxamide;bromide Chemical compound [Br-].C12=CC=CC=C2C2=CC=CC=C2C1(O)C(=O)NC(C(CC1)CC2)C[N+]21CCCOC1=CC=CC=C1 IBDTWHHILKDNOJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000002168 alkylating agent Substances 0.000 claims description 3
- 229940100198 alkylating agent Drugs 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- PMGRKYSNXBOJBZ-UHFFFAOYSA-N n-(1-methyl-1-azoniabicyclo[2.2.2]octan-3-yl)-9h-xanthene-9-carboxamide;bromide Chemical compound [Br-].C12=CC=CC=C2OC2=CC=CC=C2C1C(=O)NC(C1)C2CC[N+]1(C)CC2 PMGRKYSNXBOJBZ-UHFFFAOYSA-N 0.000 claims description 3
- WVXIGPWCHZXWDZ-JXJWEVJGSA-N n-[(3r)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-3-yl]-2,2-dithiophen-2-ylacetamide;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)NC(=O)C(C=3SC=CC=3)C=3SC=CC=3)[N+]21CCCOC1=CC=CC=C1 WVXIGPWCHZXWDZ-JXJWEVJGSA-N 0.000 claims description 3
- MCKIVQDSUKIVKB-CBTJMOJFSA-N n-[(3r)-1-heptyl-1-azoniabicyclo[2.2.2]octan-3-yl]-2-hydroxy-2,2-dithiophen-2-ylacetamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.N([C@@H]1C2CC[N+](CC2)(C1)CCCCCCC)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 MCKIVQDSUKIVKB-CBTJMOJFSA-N 0.000 claims description 3
- YTFWEOSNHWESFV-ZFFIDOFDSA-N n-[(3s)-1-(3-cyclohexylpropyl)-1-azoniabicyclo[2.2.2]octan-3-yl]-9h-xanthene-9-carboxamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.C([C@H](C(CC1)CC2)NC(=O)C3C4=CC=CC=C4OC4=CC=CC=C43)[N+]21CCCC1CCCCC1 YTFWEOSNHWESFV-ZFFIDOFDSA-N 0.000 claims description 3
- RYPRTVDFRFJHLK-CMYKPJMLSA-N n-[(3s)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-3-yl]-9h-xanthene-9-carboxamide;bromide Chemical compound [Br-].C([C@H](C(CC1)CC2)NC(=O)C3C4=CC=CC=C4OC4=CC=CC=C43)[N+]21CCCOC1=CC=CC=C1 RYPRTVDFRFJHLK-CMYKPJMLSA-N 0.000 claims description 3
- QDUZTLAXEGKHHE-SIMUOUHCSA-N n-[(3s)-1-[3-(5,6,7,8-tetrahydronaphthalen-2-yloxy)propyl]-1-azoniabicyclo[2.2.2]octan-3-yl]-9h-xanthene-9-carboxamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.C12=CC=CC=C2OC2=CC=CC=C2C1C(=O)N[C@H]1C(CC2)CC[N+]2(CCCOC=2C=C3CCCCC3=CC=2)C1 QDUZTLAXEGKHHE-SIMUOUHCSA-N 0.000 claims description 3
- ZOKIJORBLPTITO-WWTZQNKJSA-N n-[(3s)-1-[5-(2,6-dimethylphenoxy)pentyl]-1-azoniabicyclo[2.2.2]octan-3-yl]-9h-xanthene-9-carboxamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CC1=CC=CC(C)=C1OCCCCC[N+]1(C[C@H]2NC(=O)C3C4=CC=CC=C4OC4=CC=CC=C43)CCC2CC1 ZOKIJORBLPTITO-WWTZQNKJSA-N 0.000 claims description 3
- FCFNFLWTBVTCIX-OGZJWECNSA-N n-[(3s)-1-heptyl-1-azoniabicyclo[2.2.2]octan-3-yl]-9h-xanthene-9-carboxamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.C12=CC=CC=C2OC2=CC=CC=C2C1C(=O)N[C@H](C1)C2CC[N+]1(CCCCCCC)CC2 FCFNFLWTBVTCIX-OGZJWECNSA-N 0.000 claims description 3
- RYPRTVDFRFJHLK-UHFFFAOYSA-N n-[1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-3-yl]-9h-xanthene-9-carboxamide;bromide Chemical compound [Br-].C12=CC=CC=C2OC2=CC=CC=C2C1C(=O)NC(C(CC1)CC2)C[N+]21CCCOC1=CC=CC=C1 RYPRTVDFRFJHLK-UHFFFAOYSA-N 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 125000006017 1-propenyl group Chemical group 0.000 claims description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims description 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 150000003840 hydrochlorides Chemical class 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- LBUPGUUEUUAALH-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-2-oxo-2-thiophen-2-ylacetamide Chemical compound C1N(CC2)CCC2C1NC(=O)C(=O)C1=CC=CS1 LBUPGUUEUUAALH-UHFFFAOYSA-N 0.000 claims description 2
- LBUPGUUEUUAALH-SNVBAGLBSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-2-oxo-2-thiophen-2-ylacetamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(=O)C1=CC=CS1 LBUPGUUEUUAALH-SNVBAGLBSA-N 0.000 claims description 2
- 125000002524 organometallic group Chemical group 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 239000008024 pharmaceutical diluent Substances 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 230000001575 pathological effect Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 22
- 239000005557 antagonist Substances 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 38
- 239000000243 solution Substances 0.000 description 26
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 239000000543 intermediate Substances 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 5
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 5
- RYPRTVDFRFJHLK-XDVWKIBCSA-N n-[(3r)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-3-yl]-9h-xanthene-9-carboxamide;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)NC(=O)C3C4=CC=CC=C4OC4=CC=CC=C43)[N+]21CCCOC1=CC=CC=C1 RYPRTVDFRFJHLK-XDVWKIBCSA-N 0.000 description 5
- BGJHKTPRUFXYHT-ZVAWYAOSSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-phenylhexanamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(CCCC)C1=CC=CC=C1 BGJHKTPRUFXYHT-ZVAWYAOSSA-N 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 208000023504 respiratory system disease Diseases 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- NEJIORLSCLGYLQ-VLJFIYOESA-N 2-hydroxy-n-[(3r)-1-[3-(3-hydroxyphenoxy)propyl]-1-azoniabicyclo[2.2.2]octan-3-yl]-2,2-dithiophen-2-ylacetamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.OC1=CC=CC(OCCC[N+]23CCC(CC2)[C@H](C3)NC(=O)C(O)(C=2SC=CC=2)C=2SC=CC=2)=C1 NEJIORLSCLGYLQ-VLJFIYOESA-N 0.000 description 4
- 208000009079 Bronchial Spasm Diseases 0.000 description 4
- 208000014181 Bronchial disease Diseases 0.000 description 4
- 206010006482 Bronchospasm Diseases 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 125000002723 alicyclic group Chemical group 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000007941 film coated tablet Substances 0.000 description 3
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical class OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- LBUPGUUEUUAALH-JTQLQIEISA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-oxo-2-thiophen-2-ylacetamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(=O)C1=CC=CS1 LBUPGUUEUUAALH-JTQLQIEISA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- XOFMKTIZCDSXFR-UHFFFAOYSA-N 2,2-dithiophen-2-ylacetic acid Chemical compound C=1C=CSC=1C(C(=O)O)C1=CC=CS1 XOFMKTIZCDSXFR-UHFFFAOYSA-N 0.000 description 2
- PMCNGVWJGLTDLF-UHFFFAOYSA-N 2-cyclopentyl-2-hydroxy-2-thiophen-2-ylacetic acid Chemical compound C=1C=CSC=1C(O)(C(=O)O)C1CCCC1 PMCNGVWJGLTDLF-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010063057 Cystitis noninfective Diseases 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- 206010040741 Sinus bradycardia Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 2
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- VSBFNCXKYIEYIS-UHFFFAOYSA-N Xanthene-9-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)C3=CC=CC=C3OC2=C1 VSBFNCXKYIEYIS-UHFFFAOYSA-N 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000000043 antiallergic agent Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- 230000010083 bronchial hyperresponsiveness Effects 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 201000003139 chronic cystitis Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 208000007784 diverticulitis Diseases 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 125000005956 isoquinolyl group Chemical group 0.000 description 2
- SNHOZPMHMQQMNI-UHFFFAOYSA-N lithium;2h-thiophen-2-ide Chemical compound [Li+].C=1C=[C-]SC=1 SNHOZPMHMQQMNI-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 229910000000 metal hydroxide Inorganic materials 0.000 description 2
- 150000004692 metal hydroxides Chemical class 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000003551 muscarinic effect Effects 0.000 description 2
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 2
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000001734 parasympathetic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000001453 quaternary ammonium group Chemical class 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000005493 quinolyl group Chemical group 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 230000001148 spastic effect Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 208000014001 urinary system disease Diseases 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- IGNPOXGBNFMJHE-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-2-amine Chemical compound C1CN2C(N)CC1CC2 IGNPOXGBNFMJHE-UHFFFAOYSA-N 0.000 description 1
- REUAXQZIRFXQML-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-amine Chemical compound C1CC2C(N)CN1CC2 REUAXQZIRFXQML-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- FSEUPAGRZRSEMG-ZVWPAMIASA-N 2-(furan-2-yl)-2-hydroxy-4-(4-methoxyphenyl)-n-[(3r)-1-[6-(4-phenylbutoxy)hexyl]-1-azoniabicyclo[2.2.2]octan-3-yl]butanamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.C1=CC(OC)=CC=C1CCC(O)(C=1OC=CC=1)C(=O)N[C@@H]1C(CC2)CC[N+]2(CCCCCCOCCCCC=2C=CC=CC=2)C1 FSEUPAGRZRSEMG-ZVWPAMIASA-N 0.000 description 1
- VNEPYOMPHNXXBR-YHAVVQIFSA-N 2-(furan-2-yl)-2-hydroxy-n-[(3r)-1-(3-naphthalen-1-yloxypropyl)-1-azoniabicyclo[2.2.2]octan-3-yl]pent-3-ynamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.N([C@@H]1C2CC[N+](CC2)(CCCOC=2C3=CC=CC=C3C=CC=2)C1)C(=O)C(O)(C#CC)C1=CC=CO1 VNEPYOMPHNXXBR-YHAVVQIFSA-N 0.000 description 1
- TUCRZHGAIRVWTI-UHFFFAOYSA-N 2-bromothiophene Chemical compound BrC1=CC=CS1 TUCRZHGAIRVWTI-UHFFFAOYSA-N 0.000 description 1
- HJVYGJBCYGAKMJ-KIIFLFPXSA-N 2-cyclopentyl-2-hydroxy-2-thiophen-2-yl-n-[(3r)-1-(4,4,4-trifluorobutyl)-1-azoniabicyclo[2.2.2]octan-3-yl]acetamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.N([C@@H]1C2CC[N+](CC2)(CCCC(F)(F)F)C1)C(=O)C(C=1SC=CC=1)(O)C1CCCC1 HJVYGJBCYGAKMJ-KIIFLFPXSA-N 0.000 description 1
- IZMWQEYESGMFJI-ZHZOXGDSSA-N 2-cyclopentyl-2-hydroxy-n-[(3r)-1-[2-[2-(2-hydroxyethoxy)ethoxy]ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl]-2-thiophen-2-ylacetamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.N([C@@H]1C2CC[N+](CC2)(C1)CCOCCOCCO)C(=O)C(O)(C=1SC=CC=1)C1CCCC1 IZMWQEYESGMFJI-ZHZOXGDSSA-N 0.000 description 1
- CSXIOKNCHLDRPK-WWCJRKCVSA-N 2-cyclopentyl-n-[(3r)-1-(2-ethoxyethyl)-1-azoniabicyclo[2.2.2]octan-3-yl]-2-hydroxy-2-thiophen-2-ylacetamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.N([C@@H]1C2CC[N+](CC2)(C1)CCOCC)C(=O)C(O)(C=1SC=CC=1)C1CCCC1 CSXIOKNCHLDRPK-WWCJRKCVSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- PGIOANNVJQQCDT-UHFFFAOYSA-N 2-phenylhexanoic acid Chemical compound CCCCC(C(O)=O)C1=CC=CC=C1 PGIOANNVJQQCDT-UHFFFAOYSA-N 0.000 description 1
- PEMWIZXTFVQMED-UHFFFAOYSA-N 3-(3-chloropropoxy)phenol Chemical compound OC1=CC=CC(OCCCCl)=C1 PEMWIZXTFVQMED-UHFFFAOYSA-N 0.000 description 1
- NIDWUZTTXGJFNN-UHFFFAOYSA-N 3-bromopropoxybenzene Chemical compound BrCCCOC1=CC=CC=C1 NIDWUZTTXGJFNN-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- FCIUNVQLCMYTAA-ZVPZRTFFSA-N 4-[(3r)-3-[[2-(5-bromothiophen-2-yl)-2-(4-fluoro-3-methylphenyl)-2-hydroxyacetyl]amino]-1-azoniabicyclo[2.2.2]octan-1-yl]butyl acetate;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.N([C@@H]1C2CC[N+](CC2)(C1)CCCCOC(=O)C)C(=O)C(O)(C=1C=C(C)C(F)=CC=1)C1=CC=C(Br)S1 FCIUNVQLCMYTAA-ZVPZRTFFSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- SCAPXGYRLDOZEH-KZKVJHKASA-N 9-hydroxy-n-[(3r)-1-(3-phenylsulfanylpropyl)-1-azoniabicyclo[2.2.2]octan-3-yl]fluorene-9-carboxamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.C([C@@H](C(CC1)CC2)NC(=O)C3(O)C4=CC=CC=C4C4=CC=CC=C43)[N+]21CCCSC1=CC=CC=C1 SCAPXGYRLDOZEH-KZKVJHKASA-N 0.000 description 1
- PQGNPGIXILKIFA-JLKBBCKKSA-N 9-hydroxy-n-[(3r)-1-(4-oxo-4-thiophen-2-ylbutyl)-1-azoniabicyclo[2.2.2]octan-3-yl]fluorene-9-carboxamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.C([C@@H](C(CC1)CC2)NC(=O)C3(O)C4=CC=CC=C4C4=CC=CC=C43)[N+]21CCCC(=O)C1=CC=CS1 PQGNPGIXILKIFA-JLKBBCKKSA-N 0.000 description 1
- JZOYCAAEAASOQO-STNBFCITSA-N 9-hydroxy-n-[(3r)-1-[3-(n-methylanilino)propyl]-1-azoniabicyclo[2.2.2]octan-3-yl]fluorene-9-carboxamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.C1CC([C@H](C2)NC(=O)C3(O)C4=CC=CC=C4C4=CC=CC=C43)CC[N+]12CCCN(C)C1=CC=CC=C1 JZOYCAAEAASOQO-STNBFCITSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 241000854350 Enicospilus group Species 0.000 description 1
- GXAMYUGOODKVRM-UHFFFAOYSA-N Flurecol Chemical compound C1=CC=C2C(C(=O)O)(O)C3=CC=CC=C3C2=C1 GXAMYUGOODKVRM-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010020853 Hypertonic bladder Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 1
- 206010029279 Neurogenic bladder Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 1
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 1
- YIOLGOWFHRDXOI-UHFFFAOYSA-N [Mg]C1=CC=CS1 Chemical compound [Mg]C1=CC=CS1 YIOLGOWFHRDXOI-UHFFFAOYSA-N 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000001022 anti-muscarinic effect Effects 0.000 description 1
- 150000003974 aralkylamines Chemical class 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 229940124748 beta 2 agonist Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- UUWSLBWDFJMSFP-UHFFFAOYSA-N bromomethylcyclohexane Chemical compound BrCC1CCCCC1 UUWSLBWDFJMSFP-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical class 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- XMGVKPGSFGMJKS-BAJVQQJVSA-N ethyl 5-[(3r)-3-[[2-(5-bromothiophen-2-yl)-2-(4-fluoro-3-methylphenyl)-2-hydroxyacetyl]amino]-1-azoniabicyclo[2.2.2]octan-1-yl]pentanoate;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.N([C@@H]1C2CC[N+](CC2)(C1)CCCCC(=O)OCC)C(=O)C(O)(C=1C=C(C)C(F)=CC=1)C1=CC=C(Br)S1 XMGVKPGSFGMJKS-BAJVQQJVSA-N 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 description 1
- JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000000050 ionisation spectroscopy Methods 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- HZUKZELWMDCYOZ-UHFFFAOYSA-N methyl 2,2-dithiophen-2-ylacetate Chemical compound C=1C=CSC=1C(C(=O)OC)C1=CC=CS1 HZUKZELWMDCYOZ-UHFFFAOYSA-N 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- OWVHFWXCTJLOAC-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-n-ethyl-9h-xanthene-9-carboxamide Chemical compound C12=CC=CC=C2OC2=CC=CC=C2C1C(=O)N(CC)C1C(CC2)CCN2C1 OWVHFWXCTJLOAC-UHFFFAOYSA-N 0.000 description 1
- GZYGHLOFWVNJOI-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-n-methyl-9h-xanthene-9-carboxamide Chemical compound C12=CC=CC=C2OC2=CC=CC=C2C1C(=O)N(C)C1C(CC2)CCN2C1 GZYGHLOFWVNJOI-UHFFFAOYSA-N 0.000 description 1
- MYCSDFQNJITDAO-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-4-yl)-2-cyclopentyl-2-hydroxy-2-thiophen-2-ylacetamide Chemical compound C1CN(CC2)CCC12NC(=O)C(C=1SC=CC=1)(O)C1CCCC1 MYCSDFQNJITDAO-UHFFFAOYSA-N 0.000 description 1
- BUVFUKGWZXJAOZ-DONHNUADSA-N n-[(3r)-1-(3-amino-3-oxopropyl)-1-azoniabicyclo[2.2.2]octan-3-yl]-2-hydroxy-2-thiophen-2-ylpent-4-enamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.N([C@@H]1C2CC[N+](CC2)(C1)CCC(=O)N)C(=O)C(O)(CC=C)C1=CC=CS1 BUVFUKGWZXJAOZ-DONHNUADSA-N 0.000 description 1
- LDIDOSSNHCVRLI-GFUFQGNZSA-N n-[(3r)-1-(3-cyanopropyl)-1-azoniabicyclo[2.2.2]octan-3-yl]-2-hydroxy-2-phenyl-2-thiophen-2-ylacetamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.N([C@@H]1C2CC[N+](CC2)(CCCC#N)C1)C(=O)C(O)(C=1C=CC=CC=1)C1=CC=CS1 LDIDOSSNHCVRLI-GFUFQGNZSA-N 0.000 description 1
- XVAGDUYMEKIXPM-AFQVKWIVSA-N n-[(3r)-1-[3-(1,3-benzothiazol-2-yloxy)propyl]-1-azoniabicyclo[2.2.2]octan-3-yl]-2-hydroxy-2-phenyl-2-thiophen-2-ylacetamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.N([C@@H]1C2CC[N+](CC2)(CCCOC=2SC3=CC=CC=C3N=2)C1)C(=O)C(O)(C=1C=CC=CC=1)C1=CC=CS1 XVAGDUYMEKIXPM-AFQVKWIVSA-N 0.000 description 1
- ODMATUGAOCKIGY-SJEMYQCASA-N n-[(3r)-1-[4-(4-fluorophenyl)-4-oxobutyl]-1-azoniabicyclo[2.2.2]octan-3-yl]-9-hydroxyfluorene-9-carboxamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.C([C@@H](C(CC1)CC2)NC(=O)C3(O)C4=CC=CC=C4C4=CC=CC=C43)[N+]21CCCC(=O)C1=CC=C(F)C=C1 ODMATUGAOCKIGY-SJEMYQCASA-N 0.000 description 1
- UMZFFLLCFIKQSR-DJZRFWRSSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-(5-bromothiophen-2-yl)-2-(4-fluoro-3-methylphenyl)-2-hydroxyacetamide Chemical compound C1=C(F)C(C)=CC(C(O)(C(=O)N[C@@H]2C3CCN(CC3)C2)C=2SC(Br)=CC=2)=C1 UMZFFLLCFIKQSR-DJZRFWRSSA-N 0.000 description 1
- QSFVQDXXWKQPKI-MBIQTGHCSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-(furan-3-yl)-2-hydroxy-2-thiophen-2-ylacetamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(O)(C=1SC=CC=1)C=1C=COC=1 QSFVQDXXWKQPKI-MBIQTGHCSA-N 0.000 description 1
- QKYYSDPGTMVINO-KKFHFHRHSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-cyclohexyl-2-hydroxy-2-thiophen-3-ylacetamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(C1=CSC=C1)(O)C1CCCCC1 QKYYSDPGTMVINO-KKFHFHRHSA-N 0.000 description 1
- LGZKEUFXLRXCRP-UCFFOFKASA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-hydroxy-2-phenyl-2-thiophen-2-ylacetamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(O)(C=1C=CC=CC=1)C1=CC=CS1 LGZKEUFXLRXCRP-UCFFOFKASA-N 0.000 description 1
- PSFULERNVNPNAD-IBGZPJMESA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-9-hydroxyfluorene-9-carboxamide Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1(O)C(=O)N[C@@H]1C(CC2)CCN2C1 PSFULERNVNPNAD-IBGZPJMESA-N 0.000 description 1
- SLPKWZVKESFSQR-UHFFFAOYSA-M n-methyl-n-[1-(3-pyrrol-1-ylpropyl)-1-azoniabicyclo[2.2.2]octan-3-yl]-9h-xanthene-9-carboxamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.C12=CC=CC=C2OC2=CC=CC=C2C1C(=O)N(C)C(C(CC1)CC2)C[N+]21CCCN1C=CC=C1 SLPKWZVKESFSQR-UHFFFAOYSA-M 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229920000075 poly(4-vinylpyridine) Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- RKIIRJKCZOGESH-QVOXVMGDSA-N s-[3-[(3r)-3-[[2-(5-bromothiophen-2-yl)-2-(4-fluoro-3-methylphenyl)-2-hydroxyacetyl]amino]-1-azoniabicyclo[2.2.2]octan-1-yl]propyl] ethanethioate;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.N([C@@H]1C2CC[N+](CC2)(C1)CCCSC(=O)C)C(=O)C(O)(C=1C=C(C)C(F)=CC=1)C1=CC=C(Br)S1 RKIIRJKCZOGESH-QVOXVMGDSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000016978 synaptic transmission, cholinergic Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 229960004847 urologicals Drugs 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (25)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200201539A ES2204295B1 (es) | 2002-07-02 | 2002-07-02 | Nuevos derivados de quinuclidina-amida. |
| DE60332534T DE60332534D1 (de) | 2002-07-02 | 2003-06-25 | Chinuclidinamidderivate |
| UAA200500839A UA80832C2 (en) | 2002-07-02 | 2003-06-25 | Quinuclidine amide derivatives |
| EP03762514A EP1519933B1 (en) | 2002-07-02 | 2003-06-25 | Quinuclidine amide derivatives |
| JP2004518575A JP2005533826A (ja) | 2002-07-02 | 2003-06-25 | 新規なるキヌクリジンアミド誘導体 |
| RU2005102585/04A RU2314306C2 (ru) | 2002-07-02 | 2003-06-25 | Производные хинуклидинамида, способ их получения и их применение, фармацевтическая композиция, комбинированный продукт и способ ингибирования мускариновых рецепторов |
| AU2003242757A AU2003242757B2 (en) | 2002-07-02 | 2003-06-25 | New quinuclidine amide derivatives |
| CA002492535A CA2492535A1 (en) | 2002-07-02 | 2003-06-25 | New quinuclidine amide derivatives |
| NZ537341A NZ537341A (en) | 2002-07-02 | 2003-06-25 | Quinuclidine amide derivatives as antimuscarinic agents to treat respiratory disorders |
| AT03762514T ATE467631T1 (de) | 2002-07-02 | 2003-06-25 | Chinuclidinamidderivate |
| US10/518,714 US7488735B2 (en) | 2002-07-02 | 2003-06-25 | Quinuclidine amide derivatives |
| CNB03820648XA CN100404533C (zh) | 2002-07-02 | 2003-06-25 | 奎宁环酰胺衍生物 |
| BR0312216-6A BR0312216A (pt) | 2002-07-02 | 2003-06-25 | Composto, processo para a produção de um composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito que sofre de uma doença ou condição patológica e combinação de produto |
| MXPA04012271A MXPA04012271A (es) | 2002-07-02 | 2003-06-25 | Nuevos derivados de quinuclidina-amida. |
| PCT/EP2003/006708 WO2004005285A1 (en) | 2002-07-02 | 2003-06-25 | New quinuclidine amide derivatives |
| UY27870A UY27870A1 (es) | 2002-07-02 | 2003-06-27 | Nuevos derivados de quinuclidina-amida |
| MYPI20032447A MY130803A (en) | 2002-07-02 | 2003-06-30 | New quinuclidine amide derivatives |
| PE2003000662A PE20040644A1 (es) | 2002-07-02 | 2003-06-30 | Nuevos derivados de quinuclidina-amina |
| ARP030102368A AR040351A1 (es) | 2002-07-02 | 2003-06-30 | Derivados de quinuclidina-amida, composicion farmaceutica, procedimiento de preparacion del compuesto y su uso para fabricar medicamentos |
| TW092118081A TW200402420A (en) | 2002-07-02 | 2003-07-02 | New quinuclidine amide derivatives |
| IL165923A IL165923A (en) | 2002-07-02 | 2004-12-22 | Quinuclidine amide derivatives, process for producing, uses, compositions and combination products comprising them |
| ZA200410404A ZA200410404B (en) | 2002-07-02 | 2004-12-23 | New quinuclidine amide derivatives. |
| EC2004005519A ECSP045519A (es) | 2002-07-02 | 2004-12-29 | Nuevos derivados de quinuclidina-amida |
| NO20050164A NO20050164L (no) | 2002-07-02 | 2005-01-12 | Nye quinuklidin-amid-derivater |
| US11/970,698 US7718670B2 (en) | 2002-07-02 | 2008-01-08 | Quinuclidine amide derivatives |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200201539A ES2204295B1 (es) | 2002-07-02 | 2002-07-02 | Nuevos derivados de quinuclidina-amida. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2204295A1 ES2204295A1 (es) | 2004-04-16 |
| ES2204295B1 true ES2204295B1 (es) | 2005-08-01 |
Family
ID=30011350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES200201539A Expired - Fee Related ES2204295B1 (es) | 2002-07-02 | 2002-07-02 | Nuevos derivados de quinuclidina-amida. |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7488735B2 (https=) |
| EP (1) | EP1519933B1 (https=) |
| JP (1) | JP2005533826A (https=) |
| CN (1) | CN100404533C (https=) |
| AR (1) | AR040351A1 (https=) |
| AT (1) | ATE467631T1 (https=) |
| AU (1) | AU2003242757B2 (https=) |
| BR (1) | BR0312216A (https=) |
| CA (1) | CA2492535A1 (https=) |
| DE (1) | DE60332534D1 (https=) |
| EC (1) | ECSP045519A (https=) |
| ES (1) | ES2204295B1 (https=) |
| IL (1) | IL165923A (https=) |
| MX (1) | MXPA04012271A (https=) |
| MY (1) | MY130803A (https=) |
| NO (1) | NO20050164L (https=) |
| NZ (1) | NZ537341A (https=) |
| PE (1) | PE20040644A1 (https=) |
| RU (1) | RU2314306C2 (https=) |
| TW (1) | TW200402420A (https=) |
| UA (1) | UA80832C2 (https=) |
| UY (1) | UY27870A1 (https=) |
| WO (1) | WO2004005285A1 (https=) |
| ZA (1) | ZA200410404B (https=) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| JP4445704B2 (ja) | 2000-12-22 | 2010-04-07 | アルミラル・ソシエダッド・アノニマ | キヌクリジンカルバメート誘導体およびｍ３アンダゴニストとしてのそれらの使用 |
| ES2203327B1 (es) | 2002-06-21 | 2005-06-16 | Almirall Prodesfarma, S.A. | Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen. |
| TW200519106A (en) | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
| GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| ES2239546B1 (es) * | 2004-03-15 | 2006-12-01 | Almirall Prodesfarma, S.A. | Nuevos esteres de quinuclidina cuaternizados. |
| PE20060259A1 (es) * | 2004-04-27 | 2006-03-25 | Glaxo Group Ltd | Compuestos de quinuclidina como antagonistas del receptor de acetilcolina muscarinico |
| JP2007537261A (ja) * | 2004-05-13 | 2007-12-20 | グラクソ グループ リミテッド | ムスカリン性アセチルコリン受容体アンタゴニスト |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| ES2246170B1 (es) * | 2004-07-29 | 2007-04-01 | Almirall Prodesfarma, S.A. | Nuevo procedimiento para preparar derivados de carbamato de quinuclidinio. |
| JP4781362B2 (ja) * | 2004-09-15 | 2011-09-28 | 書強 趙 | ４級アンモニウム基を有するキヌクリジン化合物とその調製方法、およびアセチルコリン遮断剤としての用途 |
| GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| RU2421464C2 (ru) | 2005-10-21 | 2011-06-20 | Новартис Аг | Человеческие антитела к il-13 и их терапевтическое применение |
| US9088384B2 (en) * | 2005-10-27 | 2015-07-21 | Qualcomm Incorporated | Pilot symbol transmission in wireless communication systems |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| EP2322525B1 (en) | 2006-04-21 | 2013-09-18 | Novartis AG | Purine derivatives for use as adenosin A2A receptor agonists |
| ES2298049B1 (es) * | 2006-07-21 | 2009-10-20 | Laboratorios Almirall S.A. | Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano. |
| WO2008037477A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as p13k lipid kinase inhibitors |
| PL2104535T3 (pl) | 2007-01-10 | 2011-05-31 | Irm Llc | Związki i kompozycje jako inhibitory proteazy aktywujące kanały |
| ES2554646T3 (es) * | 2007-02-23 | 2015-12-22 | Theravance Biopharma R&D Ip, Llc | Compuestos de difenilmetilo de amonio cuaternario, de utilidad como antagonistas de receptores muscarínicos |
| DE602008005140D1 (de) | 2007-05-07 | 2011-04-07 | Novartis Ag | Organische verbindungen |
| MX2010006421A (es) | 2007-12-10 | 2010-06-25 | Novartis Ag | Compuestos organicos. |
| MX2010007604A (es) | 2008-01-11 | 2010-08-02 | Novartis Ag | Pirimidinas como inhibidores de cinasa. |
| WO2009098455A1 (en) * | 2008-02-06 | 2009-08-13 | Astrazeneca Ab | 2- (9h-xanthen-9-yl) -oxazol derivatives as m3 muscarinic receptor antagonists for the treatment of asthma and chronic obstructive lung disease |
| WO2009098453A1 (en) * | 2008-02-06 | 2009-08-13 | Astrazeneca Ab | Azonia bicycloalkanes as m3 muscarinic acetylcholin receptor antagonists |
| EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
| JP2011522860A (ja) | 2008-06-10 | 2011-08-04 | ノバルティス アーゲー | 上皮性ナトリウムチャネルブロッカーとしてのピラジン誘導体 |
| GB0814729D0 (en) * | 2008-08-12 | 2008-09-17 | Argenta Discovery Ltd | New combination |
| GB0814728D0 (en) * | 2008-08-12 | 2008-09-17 | Argenta Discovery Ltd | New combination |
| CA2733449A1 (en) * | 2008-08-12 | 2010-02-18 | Astrazeneca Ab | 2-hydroxy-ethanesulfonate salt |
| PT2391366E (pt) | 2009-01-29 | 2013-02-05 | Novartis Ag | Benzimidazoles substituídos para o tratamento de astrocitomas |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| JP5781510B2 (ja) | 2009-08-12 | 2015-09-24 | ノバルティス アーゲー | ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用 |
| PE20121148A1 (es) | 2009-08-17 | 2012-09-07 | Intellikine Llc | Compuestos heterociclicos y usos de los mismos |
| JP5775871B2 (ja) | 2009-08-20 | 2015-09-09 | ノバルティス アーゲー | ヘテロ環式オキシム化合物 |
| MX2012004792A (es) | 2009-10-22 | 2013-02-01 | Vertex Pharma | Composiciones para el tratamiento de fibrosis quistica y otras enfermedades cronicas. |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
| WO2012107500A1 (en) | 2011-02-10 | 2012-08-16 | Novartis Ag | [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
| WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
| WO2012116217A1 (en) | 2011-02-25 | 2012-08-30 | Irm Llc | Compounds and compositions as trk inhibitors |
| EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
| CA2834467A1 (en) * | 2011-04-29 | 2012-11-01 | Chiesi Farmaceutici S.P.A. | Alkaloid ester and carbamate derivatives and medicinal compositions thereof |
| US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
| EA026655B1 (ru) | 2011-09-15 | 2017-05-31 | Новартис Аг | 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ |
| CN103946221B (zh) | 2011-09-16 | 2016-08-03 | 诺华股份有限公司 | 用于治疗囊性纤维化的杂环化合物 |
| WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
| WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| US9056867B2 (en) | 2011-09-16 | 2015-06-16 | Novartis Ag | N-substituted heterocyclyl carboxamides |
| WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| CA2856803A1 (en) | 2011-11-23 | 2013-05-30 | Intellikine, Llc | Enhanced treatment regimens using mtor inhibitors |
| US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
| JP2015512425A (ja) | 2012-04-03 | 2015-04-27 | ノバルティス アーゲー | チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用 |
| US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
| EP2968340A4 (en) | 2013-03-15 | 2016-08-10 | Intellikine Llc | COMBINING KINASE INHIBITORS AND USES THEREOF |
| EP3023424B1 (en) * | 2013-07-13 | 2019-02-27 | Beijing Shuobai Pharmaceutical Co., Ltd. | Quinine compounds, and optical isomers, preparation method and medical use thereof |
| WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
| EP3134397A1 (en) | 2014-04-24 | 2017-03-01 | Novartis AG | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| KR20160145780A (ko) | 2014-04-24 | 2016-12-20 | 노파르티스 아게 | 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체 |
| KR20160141856A (ko) | 2014-04-24 | 2016-12-09 | 노파르티스 아게 | 포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체 |
| US10100012B2 (en) * | 2014-05-30 | 2018-10-16 | Sphaera Pharma Pvt. Ltd. | Compounds as anti-tubercular agents |
| WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
| ES2831416T3 (es) | 2014-07-31 | 2021-06-08 | Novartis Ag | Terapia de combinación de un inhibidor de MET y un inhibidor de EGFR |
| WO2020250116A1 (en) | 2019-06-10 | 2020-12-17 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis |
| PE20220346A1 (es) | 2019-08-28 | 2022-03-14 | Novartis Ag | Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades |
| CN110759904B (zh) * | 2019-10-21 | 2023-03-14 | 河南科技大学 | 9r-酰氧基奎宁类衍生物及其制备方法、奎宁或其衍生物的应用、植物源杀虫剂 |
| TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2762796A (en) | 1956-09-11 | Iminodibenzyl derivative | ||
| GB1219606A (en) * | 1968-07-15 | 1971-01-20 | Rech S Et D Applic Scient Soge | Quinuclidinol derivatives and preparation thereof |
| GB1246606A (en) | 1969-04-28 | 1971-09-15 | Starogardzkie Zakl Farma | Dibenzo-azepine derivatives |
| IL72788A (en) | 1984-08-28 | 1989-07-31 | Israel State | Bis quaternary oxy-bis methylene(or trimethylene)bis-n-quinuclidines,pyridines and piperidines,their preparation and antidotes against organophosphorus and carbamate poisoning containing them |
| GB2225574B (en) | 1987-12-24 | 1991-04-24 | Wyeth John & Brother Ltd | Heterocyclic compounds |
| GB8825505D0 (en) * | 1988-11-01 | 1988-12-07 | Pfizer Ltd | Therapeutic agents |
| GB8923590D0 (en) | 1989-10-19 | 1989-12-06 | Pfizer Ltd | Antimuscarinic bronchodilators |
| GB9201751D0 (en) | 1992-01-28 | 1992-03-11 | Smithkline Beecham Plc | Compounds |
| GB9202443D0 (en) | 1992-02-05 | 1992-03-18 | Fujisawa Pharmaceutical Co | A novel substituted-acetamide compound and a process for the preparation thereof |
| WO1995006635A1 (en) * | 1993-09-02 | 1995-03-09 | Yamanouchi Pharmaceutical Co., Ltd. | Carbamate derivative and medicine containing the same |
| WO1995021820A1 (en) * | 1994-02-10 | 1995-08-17 | Yamanouchi Pharmaceutical Co., Ltd. | Novel carbamate derivative and medicinal composition containing the same |
| NO2005012I1 (no) * | 1994-12-28 | 2005-06-06 | Debio Rech Pharma Sa | Triptorelin og farmasoytisk akseptable salter derav |
| ATE205490T1 (de) | 1995-10-13 | 2001-09-15 | Banyu Pharma Co Ltd | Substituierte heteroaromatische derivate |
| AUPN862996A0 (en) | 1996-03-13 | 1996-04-04 | Fujisawa Pharmaceutical Co., Ltd. | A novel substituted-acetamide compound |
| PE92198A1 (es) * | 1996-08-01 | 1999-01-09 | Banyu Pharma Co Ltd | Derivados de 1,4-piperidina disustituida que contienen fluor |
| ES2165768B1 (es) * | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| CZ294251B6 (cs) | 2000-06-27 | 2004-11-10 | Laboratorios S. A. L. V. A. T., S. A. | Karbamáty a jejich použití pro výrobu farmaceutického prostředku |
| JP4445704B2 (ja) | 2000-12-22 | 2010-04-07 | アルミラル・ソシエダッド・アノニマ | キヌクリジンカルバメート誘導体およびｍ３アンダゴニストとしてのそれらの使用 |
| IL156558A0 (en) | 2000-12-28 | 2004-01-04 | Almirall Prodesfarma Ag | Novel quinuclidine derivatives and medicinal compositions containing the same |
| EP1461336B1 (en) | 2001-12-20 | 2013-05-22 | CHIESI FARMACEUTICI S.p.A. | 1-alkyl-1-azoniabicyclo (2.2.2) octane carbamate derivatives and their use as muscarinic receptor antagonists |
| ES2203327B1 (es) | 2002-06-21 | 2005-06-16 | Almirall Prodesfarma, S.A. | Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen. |
| ATE378336T1 (de) | 2002-09-19 | 2007-11-15 | Schering Corp | Imidazopyridine als hemmstoffe cyclin abhängiger kinasen |
-
2002
- 2002-07-02 ES ES200201539A patent/ES2204295B1/es not_active Expired - Fee Related
-
2003
- 2003-06-25 US US10/518,714 patent/US7488735B2/en not_active Expired - Fee Related
- 2003-06-25 CA CA002492535A patent/CA2492535A1/en not_active Abandoned
- 2003-06-25 WO PCT/EP2003/006708 patent/WO2004005285A1/en not_active Ceased
- 2003-06-25 AT AT03762514T patent/ATE467631T1/de not_active IP Right Cessation
- 2003-06-25 CN CNB03820648XA patent/CN100404533C/zh not_active Expired - Fee Related
- 2003-06-25 AU AU2003242757A patent/AU2003242757B2/en not_active Ceased
- 2003-06-25 RU RU2005102585/04A patent/RU2314306C2/ru not_active IP Right Cessation
- 2003-06-25 JP JP2004518575A patent/JP2005533826A/ja active Pending
- 2003-06-25 UA UAA200500839A patent/UA80832C2/uk unknown
- 2003-06-25 MX MXPA04012271A patent/MXPA04012271A/es active IP Right Grant
- 2003-06-25 NZ NZ537341A patent/NZ537341A/xx unknown
- 2003-06-25 EP EP03762514A patent/EP1519933B1/en not_active Expired - Lifetime
- 2003-06-25 DE DE60332534T patent/DE60332534D1/de not_active Expired - Fee Related
- 2003-06-25 BR BR0312216-6A patent/BR0312216A/pt not_active IP Right Cessation
- 2003-06-27 UY UY27870A patent/UY27870A1/es not_active Application Discontinuation
- 2003-06-30 AR ARP030102368A patent/AR040351A1/es unknown
- 2003-06-30 PE PE2003000662A patent/PE20040644A1/es not_active Application Discontinuation
- 2003-06-30 MY MYPI20032447A patent/MY130803A/en unknown
- 2003-07-02 TW TW092118081A patent/TW200402420A/zh unknown
-
2004
- 2004-12-22 IL IL165923A patent/IL165923A/en not_active IP Right Cessation
- 2004-12-23 ZA ZA200410404A patent/ZA200410404B/xx unknown
- 2004-12-29 EC EC2004005519A patent/ECSP045519A/es unknown
-
2005
- 2005-01-12 NO NO20050164A patent/NO20050164L/no not_active Application Discontinuation
-
2008
- 2008-01-08 US US11/970,698 patent/US7718670B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP045519A (es) | 2005-03-10 |
| ZA200410404B (en) | 2005-09-05 |
| WO2004005285A1 (en) | 2004-01-15 |
| MXPA04012271A (es) | 2005-04-08 |
| CN100404533C (zh) | 2008-07-23 |
| MY130803A (en) | 2007-07-31 |
| EP1519933B1 (en) | 2010-05-12 |
| IL165923A (en) | 2010-06-30 |
| NO20050164L (no) | 2005-04-04 |
| RU2314306C2 (ru) | 2008-01-10 |
| AU2003242757A1 (en) | 2004-01-23 |
| ATE467631T1 (de) | 2010-05-15 |
| US20060167042A1 (en) | 2006-07-27 |
| AR040351A1 (es) | 2005-03-30 |
| UY27870A1 (es) | 2003-10-31 |
| UA80832C2 (en) | 2007-11-12 |
| PE20040644A1 (es) | 2004-09-18 |
| BR0312216A (pt) | 2005-04-12 |
| AU2003242757B2 (en) | 2009-01-08 |
| DE60332534D1 (de) | 2010-06-24 |
| US20080234316A1 (en) | 2008-09-25 |
| US7488735B2 (en) | 2009-02-10 |
| US7718670B2 (en) | 2010-05-18 |
| NZ537341A (en) | 2006-04-28 |
| JP2005533826A (ja) | 2005-11-10 |
| RU2005102585A (ru) | 2005-10-10 |
| CA2492535A1 (en) | 2004-01-15 |
| TW200402420A (en) | 2004-02-16 |
| IL165923A0 (en) | 2006-01-15 |
| ES2204295A1 (es) | 2004-04-16 |
| CN1678610A (zh) | 2005-10-05 |
| EP1519933A1 (en) | 2005-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2204295B1 (es) | Nuevos derivados de quinuclidina-amida. | |
| ES2206021B1 (es) | Nuevos derivados de pirrolidinio. | |
| ES2266291T3 (es) | Nuevos derivados de quinuclidina y composiciones medicinales que los contienen. | |
| ES2203327B1 (es) | Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen. | |
| ES2239546B1 (es) | Nuevos esteres de quinuclidina cuaternizados. | |
| KR20050024450A (ko) | 신규한 퀴누클리딘 아미드 유도체 | |
| HK1101855B (en) | New quaternized quinuclidine esters |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EC2A | Search report published |
Date of ref document: 20040416 Kind code of ref document: A1 |
|
| FD2A | Announcement of lapse in spain |
Effective date: 20180808 |